Nadofaragene Firadenovec: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Nadofaragene Firadenovec. Educational only — not medical advice.
Labeled uses
ADSTILADRIN® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Source: FDA labeling via NIH DailyMed (set 5ca20ed4…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.